Contact: Kathryn Ryan, 914-740-2100, firstname.lastname@example.org
Do Cannabis Users Think Package Warnings Are Needed?
New Rochelle, NY, December 6, 2016—Legalization of cannabis for medical or leisure use is increasing in the U.S., and many experts and cannabis users alike agree that package warnings stating the health risks are needed. The warnings suggested by cannabis users are not necessarily the same as those of medical experts though, as shown in a new study published in Cannabis and Cannabinoid Research, a new peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cannabis and Cannabinoid Research website.
In the article "Cannabis Users’ Recommended Warnings for Packages of Legally Sold Cannabis: An Australia-Centered Study," authors John Malouff, Caitlin Johnson, University of New England, and Sally Rooke, University of Sydney, Australia, asked young adults who had used cannabis at least once to suggest a warning that governments could mandate on cannabis packages. Some youths in Australia view cannabis as potentially harmful, and many of their recommended warnings agreed with those of experts, particularly related to the effects of cannabis on driving ability, mental health and psychological functioning, addiction/abuse risk, and long-term physical effects. However, the study participants also suggested some types of warnings not typically recommended by experts.
“One of the many challenges created by legalization is how to package cannabis products,” says Editor-in-Chief Daniele Piomelli, PhD, University of California-Irvine, School of Medicine. “This is no small problem: think how different a box of gummy bears and a bottle of medications look, and how this difference can influence use. We hope that this contribution will be the first of several examining this issue from different perspectives.”
About the Journal
Cannabis and Cannabinoid Research is the only peer-reviewed open access journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. Led by Editor-in-Chief Daniele Piomelli, PhD, the Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies. Complete information is available on the Cannabis and Cannabinoid Research website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Medicinal Food, The Journal of Alternative and Complementary Medicine, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.